| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Kevin M. Brennan | SVP FINANCE AND ACCOUNTING | 2026-01-02 | 1,826 | $0.64 | $1.17kSell |
| Christopher James Frankenfield | Chief Financial Officer | 2026-01-02 | 7,030 | $0.64 | $4.52kSell |
| James Samuel Shannon | Director | 2025-06-17 | 25,000 | $0.69 | $17.23kBuy |
| Rene Russo | PRESIDENT AND CEO | 2025-06-16 | 36,289 | $0.68 | $24.68kBuy |
| James Samuel Shannon | Director | 2025-06-16 | 45,000 | $0.69 | $30.87kBuy |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Gilead Sciences Inc | 17.34% | 9,105,451 | $5.42M | Insider |
| Gilead Sciences Inc | 17.34% | 9,105,451 | $5.42M | Institution |
| Yekaterina Chudnovsky | 13.33% | 7,000,000 | $4.17M | Insider |
| Bain Capital Life Sciences Investors LLC | 8.70% | 4,566,817 | $2.72M | Institution |
| Sv7 Impact Medicine Fund LP | 6.15% | 3,227,264 | $1.92M | Insider |
| Bain Capital Life Sciences Investors LLC | 5.34% | 2,805,413 | $1.67M | Insider |
| Atlas Venture Fund XI LP | 5.25% | 2,754,109 | $1.64M | Insider |
| James E. Flynn | 4.36% | 2,287,944 | $1.36M | Insider |
| Merck Co Inc | 2.83% | 1,483,758 | $882.84k | Institution |
| Takeda Pharmaceutical Co Ltd | 2.81% | 1,475,121 | $877.70k | Insider |